## ABBV: AbbVie Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.2% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($213.92)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. iSAM Funds UK Ltd Takes $3.39 Million Position in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251209T140740 | Somewhat-Bullish | Relevance: 99%
-  iSAM Funds UK Ltd has initiated a new position in AbbVie Inc. (NYSE:ABBV), purchasing 18,267 shares valued at approximately $3.39 million. This investment accounts for 0.7% of the fund's portfolio, making AbbVie its 16th largest holding. AbbVie recently raised its quarterly dividend to $1.73 and reported robust Q3 earnings, surpassing analyst expectations with $1.86 EPS on $15.78 billion in revenue.

**2. HSBC Upgrades AbbVie to Buy From Hold, Adjusts Price Target to $265 From $225**
- Source: marketscreener.com | 20251210T104529 | Bullish | Relevance: 99%
- HSBC has upgraded its rating for AbbVie Inc. (NYSE: ABBV) from "Hold" to "Buy" and increased its price target to $265 from $225. The upgrade reflects a positive outlook on the biopharmaceutical company's future performance and valuation. This decision by HSBC signals increased confidence in AbbVie's stock for investors.

**3. This AbbVie Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday**
- Source: Benzinga | 20251210T122915 | Bullish | Relevance: 99%
-  Several Wall Street analysts have upgraded their ratings for five major companies, including AbbVie, The Andersons, Wheaton Precious Metals, Terex Corporation, and EchoStar Corporation. These upgrades reflect a more bullish outlook from firms like BMO Capital, HSBC, RBC Capital, and Morgan Stanley, with increased price targets across the board. Investors interested in these stocks can find more detailed analyst opinions on Benzinga's analyst ratings page.

**4. Investment Management Corp of Ontario Has $19.88 Million Position in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251209T141736 | Bullish | Relevance: 99%
-  Investment Management Corp of Ontario significantly increased its stake in AbbVie Inc. (NYSE:ABBV) by 64.4% in the second quarter, bringing its total holdings to $19.88 million. This move is part of a broader trend of institutional investors adjusting their positions in AbbVie, which recently reported strong quarterly earnings and an increased dividend. Analysts maintain a "Moderate Buy" rating for the stock, with a consensus target price of $241.85.

**5. ASH 2025: AbbVie and Genmabâ€™s Epkinly sets new standard in second-line FL**
- Source: Yahoo Finance | 20251210T174222 | Bullish | Relevance: 99%
-  At the American Society of Hematology (ASH) Annual Meeting, AbbVie and Genmab's Epkinly, in combination with Revlimid and Rituxan, demonstrated significantly improved response rates and progression-free survival in relapsed/refractory follicular lymphoma. This triple therapy achieved an overall response rate of 95% and reduced the risk of progression or death by 79% compared to standard-of-care, setting a new benchmark for second-line treatment. The FDA has already approved this regimen, and Epkinly's global sales are projected to reach $2.6 billion by 2031, outperforming competitors in the R/R FL landscape.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | HSBC | $265 | $225 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | HSBC | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($0.06M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.1% (+0.2%)
- Blackrock Inc.: 8.3% (-1.0%)
- JPMORGAN CHASE & CO: 6.4% (+97.6%)
- State Street Corpora: 4.5% (-0.2%)
- Morgan Stanley: 2.4% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.42 indicates undervaluation relative to growth. Forward P/E 15.7x attractive for 34% earnings growth. Quality metrics strong (ROE 138%). Balance sheet: $6.5B free cash flow. Analyst sentiment positive (1 raises, avg +18%). Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $395.9B |
| Beta | 0.35 |
| 52W Range | $164.39 - $244.81 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.42 |
| Forward P/E | 15.7 |
| Current P/E | 21.0 |
| YoY Growth | 33.9% |
| EPS Direction | FALLING |

### Technicals

MRS_10 strengthening from -2.8% to -1.2% (+1.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.2pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.09x) but short-term weakness (below SMA20). MACD histogram bearish (-0.77), momentum weakening. RSI neutral at 46.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.20% (CS: 25) | Neutral |
| RSI_14 | 45.8 | Neutral |
| MACD Histogram | -0.77 | Bearish |
| vs SMA20 | 0.979x | Below |
| vs SMA50 | 0.984x | Below |
| vs SMA200 | 1.092x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $223.98
- **Stop Loss:** $213.92 (4.5% risk)
- **Target:** $234.04 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 137
- **Position Value:** $30,685.26
- **Portfolio %:** 30.69%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-06 (Est: $3.35)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $1.86 | +4.2% |
| 2025Q2 | $2.91 | $2.97 | +2.1% |
| 2025Q1 | $2.40 | $2.46 | +2.6% |
| 2024Q4 | $2.12 | $2.16 | +1.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*